Back to top
more

Coherus BioSciences (CHRS)

(Delayed Data from NSDQ)

$1.90 USD

1.90
5,241,488

-0.22 (-10.38%)

Updated May 10, 2024 04:00 PM ET

After-Market: $1.90 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CHRS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Coherus BioSciences, Inc. [CHRS]

Reports for Purchase

Showing records 21 - 40 ( 68 total )

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

03/07/2023

Company Report

Pages: 5

Set to Go Back on the Offense; Adjusting PT to $26; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

11/09/2022

Company Report

Pages: 5

Cimerli Comes to the Scene Just in Time; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

10/06/2022

Industry Report

Pages: 6

Retina In Focus; Takeaways from AAO

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

08/08/2022

Company Report

Pages: 5

Quick Thoughts After 2Q; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

08/04/2022

Daily Note

Pages: 5

A Second Commercial Product With Others in the Wings; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

05/09/2022

Company Report

Pages: 5

Challenges for 2022 But the Outlook for 2023 and Beyond Looks Bright; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

05/03/2022

Daily Note

Pages: 3

Toripalimab Receives CRL but Clinical Data Appears Sufficient; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

02/18/2022

Company Report

Pages: 5

Udenyca Continues to Feel Pricing Pressure but New Product Launches Should Help Regain Momentum; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

02/09/2022

Daily Note

Pages: 3

Toripalimab Looks in Good Stead in NPC, FDA Stance Likely Limits Competition

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

01/11/2022

Daily Note

Pages: 4

Doubling Down on Immuno-Oncology by Exercising Anti-TIGIT mAb Option; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

12/21/2021

Daily Note

Pages: 3

Coherus Biosimilars Business Shouldn’t Be Overlooked; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

12/14/2021

Daily Note

Pages: 4

Toripalimab Shows Survival Benefit in NSCLC Phase 3 Prompting BLA Discussion Request With the FDA

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

11/09/2021

Company Report

Pages: 5

Peg Market Remains Tough But Better Days Lie Ahead; Reiterate Buy, Lower PT to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

10/06/2021

Daily Note

Pages: 3

Udenyca On-Body Injector Shows Bioequivalence in Human Study with a 2022 US Submission Planned; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CHRS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

08/19/2021

Daily Note

Pages: 4

More Promising Toripalimab Data, This Time in 1st Line NSCLC; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

08/06/2021

Company Report

Pages: 5

Udenyca Starts Moving in the Right Direction Again; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

07/23/2021

Company Report

Pages: 6

Updating Our Model to Include Toripalimab; Reiterate Buy, Raise Price Target to $36

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

06/11/2021

Industry Report

Pages: 9

Takeaways From ASCO 2021 Across Our Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

06/08/2021

Daily Note

Pages: 4

Coherus Provides Overview of Toripalimab Development Strategy; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party